RxDoctor Payments Data

Wendy Bond

Nurse Practitioner · Richmond, VANPI 1093830416

Payments from drug & device makers

$2,590in general payments, 2019–2025

Across 111 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$789
  • Regeneron Healthcare Solutions, Inc.$535
  • Sanofi$217
  • GSK$171
  • Novartis$134
  • Inspire Medical Systems, Inc.$119
  • plus $626 from 16 others

What the payments were for

  • Food & beverage$2,56199%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,590 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$37,058
Medicare patients
277
Services billed
930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol67$36,359
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$23,674
DuleraMometasone/Formoterol19$8,774
Advair HfaFluticasone Propion/Salmeterol18$8,519
Arnuity ElliptaFluticasone Furoate29$6,869
SymbicortBudesonide/Formoterol Fumarate23$6,135
Ipratropium Bromide130$4,711
Wixela InhubFluticasone Propion/Salmeterol29$2,819
Azelastine Hcl68$1,759
Epinephrine16$1,669
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$1,629
Montelukast Sodium139$1,368
Albuterol Sulfate HfaAlbuterol Sulfate31$792
Fluticasone Propionate27$284
Omeprazole15$133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$171$66,902129 claims
MerckDulera$16$8,77419 claims
AstraZenecaSymbicort$789$6,13523 claims
Hikma Pharmaceuticals USAEpinephrine$21$1,66916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →